The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.The Antibody Response against HIV-1Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus proteinProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Closing the door to human immunodeficiency virus.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysAntibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virusDeterminants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelopeKinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strainsInduction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient hostThe breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LStructural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.A vaccine for HIV type 1: the antibody perspective.Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infectionEnvelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeysCross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.A Simple Mouse Model for the Study of Human Immunodeficiency Virus.Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.Anti-HIV B Cell lines as candidate vaccine biosensors.
P2860
Q24531479-F97500B7-2729-4143-8CB8-A0F95990CC6FQ27000889-61D19342-04A8-48BD-8822-A709A9E19A08Q27469558-5B9E2DDB-66B3-494E-9DA3-BF8FE62A9664Q30379200-74038AE6-5C68-4D3B-960F-518CBA74844DQ30428089-9B3FB44C-E69D-4943-8307-31CDCB0B7333Q31016954-A4264254-4D51-467E-8323-401FCC76E834Q32157115-88516E79-B114-4EAB-B7FD-2A68A5089180Q33205911-07480395-F5B8-4132-814A-9B54208FAD87Q33392865-3590A1B8-60DC-4A35-A278-C2707F6724A8Q33611645-CE31ACEF-A0B3-4730-951C-5FFED250BE75Q33647300-D5CDF4E6-2E60-44CB-9A64-68CE99D8FC49Q33649657-179E053B-1D2D-4A0F-8ED8-174AE7D70049Q33749827-72C15A42-A8CC-48BA-BCEA-443F097E42C3Q33783353-37477777-2D9F-4BF1-96FA-02CC635A8386Q33785114-13070C8F-9C5D-47A8-86EC-46F1A8A95822Q33786382-38410314-06ED-4E91-9802-3FE42606DF58Q33786386-87A60DDE-86F1-4579-B562-92E316BE4A37Q33809225-AC7B0AB2-281D-48CE-8854-286D3D009807Q33821658-A36052A1-67DA-4DC9-90FB-28A399C78A77Q33870236-EA66CFE1-2B7D-41BF-913E-948552F174CFQ33984221-66CC61F8-A0D9-454B-ADEB-F75F746C2766Q33984358-9B2E26A0-3A7D-4940-9A19-EBA6B3D39E0AQ34069214-38301874-1102-43F9-A610-D8E3049BE9E4Q34150125-9682370E-67DA-4199-AF72-0097ED5DC245Q34344205-89804E67-1166-4B3E-A82E-B0CFEF1B3760Q34472287-F2C1CEF2-7673-4557-8772-219132E5D148Q34982698-06BDF316-2E02-44D2-BCBA-28FACA243B99Q35012462-DF905B6F-47AC-49A6-AF35-591106AFB8A9Q35122067-3D07E358-A623-4096-85EC-C7EA04201295Q35880498-257D114A-72D5-4A6D-A01F-74527738F6C8Q35894716-32C988BC-2D71-4F00-A818-948BFC3D3F2BQ35992786-83298860-6719-4ABC-842E-47B3E8F0788AQ36009232-9C6BC955-88CE-4EF3-B5C5-1230F756577DQ36037760-09858436-89A8-4186-95FB-BC73BD699177Q36099376-D1B096F3-B783-4D23-B980-8BBE9CC120D1Q36155555-113FE034-BE94-4273-A84D-6148C34BA491Q36319309-8910FB88-F10D-41E9-9E4D-8D74ED70E594Q36601933-1F7F84B6-77B4-426B-8F5D-6FB63491D654Q36692987-0D84A48A-5639-48FF-A67E-188261B589ABQ36766704-27A72B80-07D3-4942-A66E-BCEEACDB105F
P2860
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The consequence of passive adm ...... s with a primary virus isolate
@ast
The consequence of passive adm ...... s with a primary virus isolate
@en
type
label
The consequence of passive adm ...... s with a primary virus isolate
@ast
The consequence of passive adm ...... s with a primary virus isolate
@en
prefLabel
The consequence of passive adm ...... s with a primary virus isolate
@ast
The consequence of passive adm ...... s with a primary virus isolate
@en
P2093
P2860
P1433
P1476
The consequence of passive adm ...... s with a primary virus isolate
@en
P2093
Katinger H
Kessler JA 2nd
Lunceford SM
Mark GE 3rd
McKenna PM
P2860
P304
P407
P577
1996-10-01T00:00:00Z